Shin Kang
Internal Medicine · Los Angeles, CANPI 1457411209
Payments from drug & device makers
Across 208 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amarin Pharma, Inc.$812
- AstraZeneca$425
- Lilly USA, LLC$406
- Amgen$325
- Nestle Healthcare Nutrition Inc.$323
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,696100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $1,019 |
| Amarin Pharma, Inc. | 34 | $812 |
| AstraZeneca | 22 | $425 |
| Lilly USA, LLC | 18 | $406 |
| Amgen | 13 | $325 |
| Nestle Healthcare Nutrition Inc. | 14 | $323 |
| Pfizer | 11 | $227 |
| Gilead | 9 | $216 |
| Novo Nordisk | 8 | $145 |
| Bayer | 7 | $139 |
| Aimmune Therapeutics, Inc. | 6 | $138 |
| Novartis | 4 | $100 |
| Vivus LLC | 4 | $93 |
| E.r. Squibb & Sons, L.L.C. | 3 | $65 |
| GSK | 2 | $38 |
| Shield Therapeutics Inc | 1 | $33 |
| Radius Health, Inc. | 1 | $30 |
| Boehringer Ingelheim | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| Ironwood Pharmaceuticals, Inc | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Boston Scientific | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EUCRISA$106
How this compares
$4,696 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 280 | $349,699 |
| JanuviaSitagliptin Phosphate | 163 | $137,773 |
| VascepaIcosapent Ethyl | 347 | $105,517 |
| TradjentaLinagliptin | 90 | $57,295 |
| EliquisApixaban | 77 | $55,098 |
| JardianceEmpagliflozin | 66 | $40,221 |
| FarxigaDapagliflozin Propanediol | 39 | $40,128 |
| TrulicityDulaglutide | 37 | $39,172 |
| Cyclosporine | 99 | $37,049 |
| RestasisCyclosporine | 42 | $33,207 |
| Tadalafil | 102 | $26,716 |
| ProliaDenosumab | 14 | $23,434 |
| XareltoRivaroxaban | 32 | $21,493 |
| Memantine Hcl ErMemantine Hcl | 116 | $20,175 |
| Icosapent Ethyl | 184 | $19,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Restasis, Linzess | $1,019 | $391,335336 claims |
| Boehringer IngelheimTradjenta, Jardiance | $25 | $97,516156 claims |
| PfizerEliquis | $227 | $55,09877 claims |
| AstraZenecaFarxiga, Brilinta | $425 | $47,10955 claims |
| Lilly USA, LLCTrulicity | $406 | $39,17237 claims |
| AmgenProlia | $325 | $23,43414 claims |
| Johnson & JohnsonXarelto | $24 | $21,49332 claims |
| GSKShingrix | $38 | $5,97129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William TownerLos Angeles$27.4M
- Herbert EradatLos Angeles$11.6M
- Deborah WongLos Angeles$10.7M
- Robin KelleyLos Angeles$5.8M
- David GuzmanLos Angeles$4.3M
- Siwen Hu-LieskovanLos Angeles$2.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.